Novo Nordisk second best in the world at providing access to medicine
17 November – Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. “Today, more than 80% of people with diabetes live in low- and middle-income countries where access to medicine and treatment is simply not adequate for the millions in need,” says CEO Lars Rebien Sørensen. “Last year, we launched our Strategy for Global Access to Diabetes Care strengthening our already existing efforts to break down barriers that inhibit access to care and help us reach 40 million people living with diabetes by 2020.”
Tianjin and Shanghai join Cities Changing Diabetes on World Diabetes Day
14 November – Today, on World Diabetes Day, the Chinese cities of Tianjin and Shanghai join the Cities Changing Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in March 2014, followed by Copenhagen in Europe and Houston in the United States last week. Lars Rebien Sørensen, chief executive officer of Novo Nordisk welcomed the global leadership the two significant cities are showing in the fight against urban diabetes: “It is my hope that by working in partnership through Cities Changing Diabetes, we can complement and support the cities’ objective to reduce the growing type 2 diabetes burden and tackle this urgent problem”. See more
Saxenda® for the treatment of obesity receives 14-1 vote in favour of approval
11 September - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda®, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity.
The panel members voted 14-1 that the overall benefit-risk assessment Saxenda® was favourable and supports approval for chronic weight management in individuals with a BMI 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbidity. “We look forward to working with the FDA as they complete their review of Saxenda®. Obesity is a serious public health issue in the US and we are committed to making Saxenda® a new treatment option for adults with obesity.”
Insulin devices - the history
See the infographic on the history of Novo Nordisk's devices (pdf)
Maintaining glycaemic control
See all the health-related infographics on pinterest
Clinical Trial Transparency
1 March - Novo Nordisk has made it easier for external researchers to get access to clinical trial data. You may read about how we conduct our clinical trials, about volunteering to participate, how we disclose trial information to the public and how researchers can access clinical trial datasets.
Read more about clinical trials.
Full-year results 2014
11 September - Read about the interaction between growth businesses and public-sector research and education. What challenges must be solved in order for research-based businesses to continue to grow in Denmark? Download the analysis in Danish or English.
25 September - Beyond conflict: Putting the focus on health in the Middle East. Read the stories in the new TBL Quarterly.
Novo Nordisk Stories
Changing Diabetes in India
11 June - In India, there are not enough healthcare professionals to meet the needs of the 65 million people with diabetes. Partnerships can change this. Find out how (PDF)